MIRA Pharmaceuticals Announces Promising Data for Ketamir-2

Leading preclinical-stage pharmaceutical business MIRA Pharmaceuticals has released fresh preclinical research data for Ketamir-2, a novel oral ketamine analogue.

As MIRA works towards submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the end of this year, which, if granted, would allow for human testing of Ketamir-2, the additional data announced today continues a string of promising preclinical results announced by MIRA in recent months for Ketamir-2.The potential of ketamir-2 to treat neurological and neuropsychiatric conditions such as depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD) is being studied.

In vitro research has shown that ketamir-2 is not a substrate for P-glycoprotein (P-gp), a membrane protein that normally pumps a variety of medications out of cells, including brain cells. This feature may help Ketamir-2, a P-gp substrate, absorb more readily via the mouth and cross the blood-brain barrier more quickly than conventional ketamine.